EGFR and neoplasm: In fact, EGFR-mutant cancer cells tend to have a lower tumor mutational burden (TMB), defined as the total number of nonsynonymous mutations per coding area of a tumor genome (Mut/Mb) [37], and to be less immunogenic compared to EGFR wild-type tumors.